OncoHost, together with its partners Heidelberg University Hospital, European Institute of Oncology and Virgen Macarena University Hospital, announced on May 15 that the parties have been awarded a €2.5 million grant from the EIC Transition Program of Horizon Europe.
In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.
